Mmbg Investment Advisors CO. Acquires 12,320 Shares of Novo Nordisk A/S (NYSE:NVO)

Mmbg Investment Advisors CO. raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 69.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,985 shares of the company's stock after purchasing an additional 12,320 shares during the quarter. Mmbg Investment Advisors CO.'s holdings in Novo Nordisk A/S were worth $2,116,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL increased its position in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the period. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $29,000. Transce3nd LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth $33,000. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth $39,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Trading Up 1.2%

Shares of Novo Nordisk A/S stock traded up $0.80 during midday trading on Friday, reaching $68.50. The company had a trading volume of 5,624,379 shares, compared to its average volume of 7,239,527. The stock has a fifty day moving average price of $69.11 and a 200 day moving average price of $77.04. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm has a market cap of $305.85 billion, a PE ratio of 20.27, a P/E/G ratio of 1.22 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $145.99.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.